- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05838911
Ergebnis der pulmonalen Rehabilitation bei Patienten mit schwerer chronisch obstruktiver Lungenerkrankung, die sich einer neuromuskulären Elektrostimulation unterziehen (NEMS for COPD)
Background: Patients with COPD often experience skeletal muscle dysfunction. For those who are unable or unwilling to undertake physical training, neuromuscular electrical stimulation (NMES) may provide an alternative method of exercise training.
Objective: To investigate the effects of adding neuromuscular electrical stimulation of gluteus maximus, quadriceps and calf muscles to chest physiotherapy, compared to chest physiotherapy alone, on muscle strength (gluteus max., quadriceps, calf muscles), femoral blood flow physical and pulmonary function in severe COPD Patients.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Material and methods: This study include a group of 60 patients (30 males and 30 females) diagnosed with severe COPD), their age is ranged 65-75 years, they will be randomly divided into two groups; study group (A) 30 patients and study group (B) 30 patients. Study group (A): The patients in this group will receive the chest physiotherapy program for 20 min each day, for five days a week for 8 consecutive weeks. Study group (B): The patients in this group will receive the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, calf muscles, performed for 30 min /day for five days a week for 8 consecutive weeks. Femoral blood Flow, gluteus maximus, quadriceps and calf muscles strength and pulmonary function (FEV1/FVC) will be measured for both groups pre and post-treatment, then after 3 months follow up.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Qina, Ägypten
- Department of P.T for internal medicine, Faculty of Physical Therapy, South valley university, Qena, Egypt
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- A diagnosis of COPD with FEV1/FVC <50% predicted as per the GOLD guidelines.
- Self-reported dyspnea and/or arm fatigue during at least one activity of daily living that required arm exercise.
- Dyspnea and/or physical activity fatigue were self-reported by the Borg Scale.
- Before entering in the study, all patients had their pulmonary function optimized with long-acting bronchodilators and corticosteroids.
Exclusion Criteria:
-
• Patients with unstable angina pectoris.
- Progressive ventricular dysrhythmia.
- Intermittent claudication.
- Implanted cardiac pacemakers.
- Uncontrolled diabetes mellitus.
- Peripheral vascular disease.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Control Group
The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for8 consecutive weeks. |
The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for 8 consecutive weeks
Andere Namen:
|
|
Experimental: Study Group
The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation (NMES) of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for 8 consecutive weeks. |
The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for 8 consecutive weeks.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Six-minute walking test (Physical function assessment
Zeitfenster: change from baseline to 8 weeks after intervention and 3 months as a follow-up
|
The six-minute walking distance (6MWD) was measured according to a standardized protocol.
|
change from baseline to 8 weeks after intervention and 3 months as a follow-up
|
|
Pulmonary function test
Zeitfenster: change from baseline to 8 weeks after intervention and 3 months as a follow-up
|
Pulmonary capacity and respiratory muscle functions will be assessed using the CPFS/D USB™ 187 Spirometer (Medical Graphics-MGC, St. Paul, MN, USA) with airflow being measured by a 188 calibrated Pitot tube (PreVent, Pneumotach). The participant completed at least three acceptable maximal forced and slow expiratory maneuvers after 15 min the inhalation of 400 mg of salbutamol 190 via a metered-dose inhaler. Forced vital capacity (FVC, L), forced expiratory volume in one second (FEV1, L), FEV1/ FVC, and inspiratory capacity (IC) will be measured according to American Thoracic Society standards |
change from baseline to 8 weeks after intervention and 3 months as a follow-up
|
|
Muscle strength measurement
Zeitfenster: change from baseline to 8 weeks after intervention and 3 months as a follow-up
|
To determine the maximal muscle strength the Lafayette manual muscle test system (USER MANUAL) (MMT) Model 01163, White Plains, New York (10602) of gluteus maximus, quadriceps and calf muscles will be measured on right lower limb. |
change from baseline to 8 weeks after intervention and 3 months as a follow-up
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Blood flow velocimetry measurement
Zeitfenster: change from baseline to 8 weeks after intervention and 3 months as a follow-up
|
To evaluate changes in peripheral perfusion. The standard pulsed-wave Doppler velocimetry of the right femoral artery was performed using sonos 2000 echograph (Philips Envisor ) |
change from baseline to 8 weeks after intervention and 3 months as a follow-up
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Ibrahim I. I Abu zaid, PhD, Department of P.T for internal medicine, Faculty of Physical Therapy, South valley university, Qena, Egypt
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- BeniSuefU_1
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .